Preoperative Serum Alpha-&lt;i&gt;L&lt;/i&gt;-Fucosidase Activity as a Prognostic Marker in Colorectal Cancer

Ayude, Daniel; Cadena, Marı́a Páez de la; Martínez-Zorzano, Vicenta S.; Fernández-Briera, Almudena; Rodrı́guez-Berrocal, Francisco Javier

doi:10.1159/000066521

Cited by 18 publications

(22 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In CRC, increased activity of lysosomal exoglycosidases in serum and urine have been reported 26, 27. The activity of α‐L‐fucosidase in serum of patients with CRC was higher in patients with distant metastases than the activity in patients with lymph node metastases, with peritoneal metastases, or without metastasis 28. The balance of the fucosylation level is regulated by fucosyltransferases and fucosidase, and the low level of fucosylation revealed in our current study may be explained by the low expression of Fut8, as indicated in this study and by the activation of α‐L‐fucosidase in patients with CRC reported by other groups 25, 27…”

Section: Discussionmentioning

confidence: 95%

Identification and assessment of new biomarkers for colorectal cancer with serum N‐glycan profiling

Zhao

Ruan

Wang

et al. 2011

Cancer

View full text Add to dashboard Cite

BACKGROUND:The objectives of this study were to identify and validate the diagnostic value of N-glycan markers in colorectal cancer (CRC) and to uncover their underlying molecular mechanism. METHODS: In total, 347 individuals, including patients with CRC, patients with colorectal adenoma, and healthy controls, were divided randomly into a training group (n ¼ 287) and retrospective validation groups (n ¼ 60). Serum N-glycan profiling was analyzed by DNA sequencer-assisted/flurophore-assisted carbohydrate electrophoresis (DSA-FACE). Two diagnostic models were constructed based on N-glycan profiling with logistic stepwise regression. The diagnostic performance of each model was assessed further in retrospective, prospective (n ¼ 43), and follow-up (n ¼ 46) cohorts. Lectin blot and reverse transcriptase-polymerase chain reaction were used to analyze the total core-fucosylated residues and molecular expression involved in core-fucosylation modifications in CRC. RESULTS: Two diagnostic models designated CRCglycoA and CRCglycoB were constructed to differentiate CRC from normal and adenoma, respectively. The areas under the receiver operating characteristic curves (AUC) of both CRCglycoA and CRCglycoB were higher than the AUC of carcinoembryonic antigen (CEA) (CRCglycoA, 0.92 vs 0.81; CRCglycoB, 0.81 vs 0.73). The sensitivity and accuracy of CRCglycoA improved from 21.7% to 25% and from 11.63% to 18% in the training cohort, the retrospective cohort, and the prospective cohorts compared with the sensitivity and accuracy of CEA. The sensitivity of CRCglycoB improved from 20% to 28.23%. Both altered N-glycans, and results from the diagnostic models were reversed after curative surgery. The level of total core fucose residues and fucosyltransferase were decreased significantly in CRC. CONCLU-SIONS: The current results indicated that the N-glycan markers based diagnostic models are new, valuable, noninvasive alternatives for identifying CRC. The authors concluded that decreased fucosyltransferase may be responsible for decreased levels of total core-fucosylated modification in both tissues and serum from patients with CRC. Cancer 2012;118:639

show abstract

Section: Discussionmentioning

confidence: 95%

Identification and assessment of new biomarkers for colorectal cancer with serum N‐glycan profiling

Zhao

Ruan

Wang

et al. 2011

Cancer

View full text Add to dashboard Cite

show abstract

“…Another study also shows that the mean value of preoperative serum AFU activity was higher in colorectal cancer (CRC) patients with distant metastases than in those with lymph node or peritoneal metastases, or without metastasis. The measurement of preoperative serum AFU activity could serve to detect hidden metastases for CRC, even before surgical intervention (Ayude et al , 2003). Most of the CRC patients with distant metastasis, for example, hepatic metastasis have a higher serum AFU level probably due to a greater flux of the enzyme from the malignant liver tissue to extracellular fluid (Deugnier et al , 1984; Takahashi et al , 1994).…”

Section: Discussionmentioning

confidence: 99%

Alpha-1-fucosidase as a prognostic indicator for hepatocellular carcinoma following hepatectomy: a large-scale, long-term study

Wang

Guo

et al. 2014

Br J Cancer

View full text Add to dashboard Cite

Background:Preoperative alpha-L-fucosidase (AFU) has been used as a diagnostic biomarker for hepatocellular carcinoma (HCC), but its role as a prognostic predictor after partial hepatectomy has not been well defined. The study aimed to investigate the prognostic significance of preoperative serum AFU for HCC patients after hepatic resection.Methods:A retrospective training data set and a prospective validation data set were used to evaluate the prognosis of HCC after partial hepatectomy. A total of 669 patients with histopathologically confirmed HCC were enrolled. Univariate and multivariate analyses were used to identify the prognostic significance of preoperative serum AFU.Results:The retrospective training data set showed a preoperative AFU>35 u l−1 should be used. The prospective validation data set showed preoperative AFU was an independent prognostic factor of overall survival (OS) (P=0.008; hazard ratio: 2.333; 95% confidence interval: 1.249–4.369). Patients with a preoperative AFU>35 u l−1 had a lower recurrence-free survival rate and an OS rate than those with AFU⩽35 u l−1, and they have a higher tendency to form macrovascular invasion. Furthermore, the prognostic significance of AFU>35 u l−1 could also be applied to patients with alpha-fetoprotein levels of ⩽400 ng ml−1.Conclusions:Preoperative serum AFU is a prognostic predictor of HCC.

show abstract

“…Considerably higher sensitivity (60%) and specificity (94% for OPC; 89% for OC) of this enzyme were observed at a threshold >450.6 U/mL, which is suggestive of its usefulness for the detection of early changes during cancer development. Similarly, α‐L‐fucosidase in serum has been reported as a promising marker for the early detection and diagnosis of hepatocellular carcinoma 21, 24, 25, 40. Ayude et al demonstrated the diagnostic and prognostic utility of decreased serum α‐L‐fucosidase activity in patients with colorectal cancer 21, 24.…”

Section: Discussionmentioning

confidence: 99%

“…It has been reported that alterations in serum and/or tissue α‐L‐fucosidase activity potentially may be useful in the diagnosis and management of cancer patients 5, 8, 21‐23. Serum α‐L‐fucosidase has been proposed as a marker for colorectal and hepatocellular carcinoma 21, 24, 25. Thus, earlier reports have encouraged interest in the use of serum fucosidase for the diagnosis of malignant diseases and as an indicator of tumor burden, metastasis, and response to anticancer treatments.…”

mentioning

confidence: 99%

Serum fucosylation changes in oral cancer and oral precancerous conditions

Shah

Telang

Raval

et al. 2008

Cancer

View full text Add to dashboard Cite

BACKGROUND. The objective of the current study was to investigate the clinical usefulness of serum fucose, fucosylated glycoproteins (fucoproteins), fucosyltransferase (FucT), and α‐L‐fucosidase in oral carcinoma. METHODS. Blood samples were collected from 130 patients with untreated oral cancer (OC), from 75 patients with oral precancerous conditions (OPC), and from 100 healthy controls. Cancer patients were followed after the initiation of anticancer treatments, and 75 follow‐up samples were also collected. Serum levels of fucose and α‐L‐fucosidase were measured spectrophotometrically. Fucoproteins were detected by using lectin‐affinity chromatography. FucT activity was analyzed by using radioassay. RESULTS. Serum levels of fucose and fucoprotein were found to be increased significantly in patients with untreated OC compared with controls, patients with OPC, and complete responders (CR) to treatment; whereas the levels were comparable between untreated patients with OC and nonresponders (NR). A similar trend was observed for serum FucT levels, and changes in enzyme activity correlated well with fucose and fucoprotein alterations. The OPC group had significantly increased fucosylation of serum proteins. Furthermore, serum α‐L‐fucosidase activity was markedly higher in patients with untreated OC and in patients with OPC compared with controls. Using receiver operating characteristic curves, a cutoff for α‐L‐fucosidase was determined at >450.6 U/mL, which showed good sensitivity and specificity in OC and OPC compared with controls. The enzyme activity was declined in the CR group but remained higher in the NR group compared with pretreatment levels. Furthermore, various clinicopathologic characteristics were correlated positively with serum fucosylation changes. CONCLUSIONS. The findings of the current study suggest that serum fucosylation has clinical usefulness in the detection of early changes and for monitoring treatment response in patients with OC. Among the markers studied, serum α‐L‐fucosidase was identified as a useful marker for close monitoring of patients during post–treatment follow‐up. Cancer 2008. © 2008 American Cancer Society.

show abstract

Preoperative Serum Alpha-<i>L</i>-Fucosidase Activity as a Prognostic Marker in Colorectal Cancer

Cited by 18 publications

References 18 publications

Identification and assessment of new biomarkers for colorectal cancer with serum N‐glycan profiling

Identification and assessment of new biomarkers for colorectal cancer with serum N‐glycan profiling

Alpha-1-fucosidase as a prognostic indicator for hepatocellular carcinoma following hepatectomy: a large-scale, long-term study

Serum fucosylation changes in oral cancer and oral precancerous conditions

Contact Info

Product

Resources

About